Current market catalysts

USA Core PPI (MoM) For August 0.2% Vs 0.3% Est.; 0.3% Prior

USA Initial Jobless Claims 206K Vs 205K Est.

8-K filing — BioCardia, Inc. (BCDA)

Filed: 2026-09-10 AccNo: 0001437749-26-030023 Size: 178 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

USA PPI (MoM) For August 0.4% Vs 0.4% Est.

Cantor Fitzgerald Maintains Overweight on Upexi, Raises Price Target to $2

Cantor Fitzgerald analyst Gareth Gacetta maintains Upexi (NASDAQ:UPXI) with a Overweight and raises the price target from $1.3 to $2.

Wells Fargo Upgrades Synopsys to Overweight, Raises Price Target to $475

Wells Fargo analyst Joe Quatrochi upgrades Synopsys (NASDAQ:SNPS) from Equal-Weight to Overweight and raises the price target from $450 to $475.

TNL Mediagene Reports August Business Insider Taiwan Website Page Views Of 1.2M+, Up From %00K In June; Plans Two New Original Flagship Video And Podcast Programs For Q4

Business Insider Taiwan streamlines the translation and editing of multilingual content across English, Chinese, and Japanese through the Company's proprietary Agentic Newsroom, an AI-driven content management

Cantor Fitzgerald Maintains Overweight on Sui Group Holdings, Raises Price Target to $3.4

Cantor Fitzgerald analyst Gareth Gacetta maintains Sui Group Holdings (NASDAQ:SUIG) with a Overweight and raises the price target from $1.7 to $3.4.

Wells Fargo Upgrades Yum Brands to Overweight, Raises Price Target to $175

Wells Fargo analyst Zachary Fadem upgrades Yum Brands (NYSE:YUM) from Equal-Weight to Overweight and raises the price target from $165 to $175.

Cantor Fitzgerald Maintains Overweight on Sol Strategies, Raises Price Target to $6.2

Cantor Fitzgerald analyst Gareth Gacetta maintains Sol Strategies (NASDAQ:STKE) with a Overweight and raises the price target from $2.8 to $6.2.

JP Morgan Upgrades Herc Holdings to Overweight, Raises Price Target to $175

JP Morgan analyst Tami Zakaria upgrades Herc Holdings (NYSE:HRI) from Neutral to Overweight and raises the price target from $165 to $175.

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

Inspire Medical, Cybin and Aveanna show overbought RSI readings above 70, signaling potential momentum warnings for healthcare investors.

Cantor Fitzgerald Maintains Overweight on Sharplink, Raises Price Target to $17

Cantor Fitzgerald analyst Gareth Gacetta maintains Sharplink (NASDAQ:SBET) with a Overweight and raises the price target from $8.3 to $17.

Ionic Digital Announces That ERCOT Provisionally Classified The Company's Remaining 466 MW Energization Request As Base Load In The Batch Zero Process

Texas-New Mexico Power ("TNMP"), the Company's interconnecting transmission service provider for the Ward County campus, informed the Company that ERCOT has provisionally classified Ionic Digital’s remaining

Piper Sandler Initiates Coverage On Intel with Neutral Rating, Announces Price Target of $110

Piper Sandler analyst David O'Connor initiates coverage on Intel (NASDAQ:INTC) with a Neutral rating and announces Price Target of $110.

JP Morgan Downgrades United Rentals to Neutral, Lowers Price Target to $1170

JP Morgan analyst Tami Zakaria downgrades United Rentals (NYSE:URI) from Overweight to Neutral and lowers the price target from $1235 to $1170.

Cantor Fitzgerald Maintains Overweight on Hyperliquid Strategies, Raises Price Target to $34.2

Cantor Fitzgerald analyst Gareth Gacetta maintains Hyperliquid Strategies (NASDAQ:PURR) with a Overweight and raises the price target from $22.6 to $34.2.

JP Morgan Upgrades Meta Platforms to Overweight, Raises Price Target to $820

JP Morgan analyst Doug Anmuth upgrades Meta Platforms (NASDAQ:META) from Neutral to Overweight and raises the price target from $640 to $820.

Macy’s Weak Profit Outlook Sends Stock Lower

Macy's (NYSE: M) stock fell in premarket trading despite a Q2 EPS beat as its weak Q3 earnings outlook weighed on investor sentiment.

Cantor Fitzgerald Maintains Overweight on Hyperion DeFi, Raises Price Target to $11.2

Cantor Fitzgerald analyst Gareth Gacetta maintains Hyperion DeFi (NASDAQ:HYPD) with a Overweight and raises the price target from $7.1 to $11.2.

8-K filing — Versus Systems Inc. (VS)

Filed: 2026-09-10 AccNo: 0001213900-26-098586 Size: 190 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

European Central Bank Raises Main Refinancing Rate From 2.40% To 2.65%

$5,000 'Trump Dividend' Echoes Past Promises: Will Bitcoin Rally Again?

Trump pledges a $5,000 dividend if Republicans keep Congress, reviving a stimulus playbook that previously sent Bitcoin sharply higher.

Jefferies Initiates Coverage On Adlai Nortye with Buy Rating, Announces Price Target of $31

Jefferies analyst Maury Raycroft initiates coverage on Adlai Nortye (NASDAQ:ANL) with a Buy rating and announces Price Target of $31.

Apple’s Foldable iPhone Could Trigger a Massive 'Upgrade Cycle,' Says Gary Black — But This One Problem Could Cap 'Incremental Earnings' for 6 Months

Gary Black predicts Apple's foldable phone will drive a new upgrade cycle but hamper incremental earnings for 6 months.

Cantor Fitzgerald Maintains Overweight on Forward Industries, Raises Price Target to $16

Cantor Fitzgerald analyst Gareth Gacetta maintains Forward Industries (NASDAQ:FWDI) with a Overweight and raises the price target from $8 to $16.

Anglogold Ashanti shares are trading lower after BMO Capital downgraded the stock from Outperform to Market Perform rating and maintained the price target at $115.

8-K filing — ONCOLYTICS BIOTECH INC (ONCY)

Filed: 2026-09-10 AccNo: 0001129928-26-000055 Size: 161 KB Item 8.01: Other Events

Cantor Fitzgerald Maintains Overweight on DeFi Development, Raises Price Target to $10.4

Cantor Fitzgerald analyst Gareth Gacetta maintains DeFi Development (NASDAQ:DFDV) with a Overweight and raises the price target from $4.7 to $10.4.

Oncolytics Biotech Announces Pelareorep Lowered Tumor Growth Compared To Control During Initial Treatment Period

Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced positive preclinical results evaluating pelareorep in